Detalle Publicación

Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center

Autores: González Padilla, Daniel Antonio (Autor de correspondencia); Subiela, J. D.; Gonzalez-Diaz, A.; Hernandez-Arroyo, M.; Garcia-Rojo, E.; Aumatell, J.; Burgos-Revilla, J.; Rodriguez-Antolin, A.; Guerrero-Ramos, F.
ISSN: 1078-1439
Volumen: 40
Número: 7
Páginas: 345.e19 - 345.e23
Fecha de publicación: 2022
Introduction: Mitomycin C (MMC) is one of the most frequently utilized intravesical chemotherapy drugs for the management of nonmuscle-invasive bladder cancer (NMIBC). Allergic reactions (Type 4 delayed hypersensitivity) are seldomly reported in the literature but not so infrequent in daily practice, its incidence has been increasing with the use of device-assisted hyperthermia. This study aims to identify the incidence, risk factors, and clinical characteristics of patients with allergic reactions to MMC. Patients and Methods: Single-center retrospective cohort from June 2014 to August 2018. Patients with intermediate or high-risk NMIBC were included. Patients received passive MMC (4 weekly and eleven monthly instillations of 40mg of MMC) or Chemo-hyperthermia (CHT) with MMC (6 weekly and 6-monthly instillations, heated at 43 degrees C [+/- 0.5 degrees C] using Combat BRS). Results: We included 258 patients (MMC = 157, CHT = 101) and found 7 (4.4%) suspected and 4 confirmed (2.4%) allergies in the passive MMC group and 11 suspected (10.9%) and 7 confirmed (6.9%) in the CHT group. The mean number of instillations received before developing the allergy was 6 in the passive MMC and 5 in the CHT group. Seven out of 18 suspected allergy cases were pseudo-allergic reactions with negative allergy tests. Early postoperative MMC instillation was associated with an increased risk of allergy (OR 2.47 [CI 1.39-4.36], P = 0.001), while neither history of atopy nor history of other medications allergy was found to increase the risk. Conclusion: MMC allergy risk is increased with the use of device-assisted hyperthermia with an incidence of 2.4% for passive MMC and 6.9% for CHT. History of prior allergies does not seem to increase the risk of developing MMC allergy. In this series 38% of suspected cases were found to be pseudo-allergic reactions, highlighting the need to confirm the diagnosis before definitively stopping the treatment. (C) 2022 Elsevier Inc. All rights reserved.